Vivesto holds a live-streamed business update today November 24
24 november, 08:00
Solna, Sweden, November 24, 2025 – Vivesto AB, an oncology-focused development company, holds a live-streamed business update today, November 24 at 15:00 CET, focusing on the recent pipeline advancements, including the positive interim efficacy results observed in the open label, clinical pilot study with Paccal Vet in dogs with splenic hemangiosarcoma following splenectomy, as well as the positive anti-cancer effects of Cantrixil shown in several preclinical hematological cancer models.
The business update will focus on the Paccal Vet and Cantrixil programs, including details about the recent results, the development plans going forward, medical needs and commercial potential.
Speakers includes:
External speakers
- Henrik Rönnberg, Professor in veterinary pharmacology (DiplECVIM-CA, oncology)
- Jim Perry, Veterinary oncologist and surgeon, DVM, PhD, CEO CASTR Alliance
- Bjørn Tore Gjersten, Professor of hematology, University of Bergen
Vivesto speakers
- Peter Zonabend, Chairman of the Board
- Erik Kinnman, CEO
- Teresa Fernandez Zafra, Chief Scientific Officer
- Johanna Röstin, Chief Regulatory Officer
- Nina Herne, Consultant, PhD, MBA, Senior Consultant
Agenda:
15.00 – 15.10 Introduction
15.10 – 15.55 Paccal Vet
Development vet industry
Key achievements dog and cat studies
Medical need and clinical studies
Development plan
15.55 – 16.15 Cantrixil
Medical need AML
Pre-clinical data
Development plans
Vet opportunity
16.15 – 16.20 Commercial potential
16.20 – 16.30 Summary
16.30 Q&A
The presentations will be followed by a Q&A session where questions can be submitted in advance via info@vivesto.com
The presentations will be held in English and can be followed via https://www.youtube.com/live/mMvLyL0w9WY and will also be available afterwards on Vivesto's website. No registration is required.
For More Information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.
Attachments
Vivesto holds a live-streamed business update today November 24
Ämnen i artikeln
Vivesto holds a live-streamed business update today November 24
24 november, 08:00
Solna, Sweden, November 24, 2025 – Vivesto AB, an oncology-focused development company, holds a live-streamed business update today, November 24 at 15:00 CET, focusing on the recent pipeline advancements, including the positive interim efficacy results observed in the open label, clinical pilot study with Paccal Vet in dogs with splenic hemangiosarcoma following splenectomy, as well as the positive anti-cancer effects of Cantrixil shown in several preclinical hematological cancer models.
The business update will focus on the Paccal Vet and Cantrixil programs, including details about the recent results, the development plans going forward, medical needs and commercial potential.
Speakers includes:
External speakers
- Henrik Rönnberg, Professor in veterinary pharmacology (DiplECVIM-CA, oncology)
- Jim Perry, Veterinary oncologist and surgeon, DVM, PhD, CEO CASTR Alliance
- Bjørn Tore Gjersten, Professor of hematology, University of Bergen
Vivesto speakers
- Peter Zonabend, Chairman of the Board
- Erik Kinnman, CEO
- Teresa Fernandez Zafra, Chief Scientific Officer
- Johanna Röstin, Chief Regulatory Officer
- Nina Herne, Consultant, PhD, MBA, Senior Consultant
Agenda:
15.00 – 15.10 Introduction
15.10 – 15.55 Paccal Vet
Development vet industry
Key achievements dog and cat studies
Medical need and clinical studies
Development plan
15.55 – 16.15 Cantrixil
Medical need AML
Pre-clinical data
Development plans
Vet opportunity
16.15 – 16.20 Commercial potential
16.20 – 16.30 Summary
16.30 Q&A
The presentations will be followed by a Q&A session where questions can be submitted in advance via info@vivesto.com
The presentations will be held in English and can be followed via https://www.youtube.com/live/mMvLyL0w9WY and will also be available afterwards on Vivesto's website. No registration is required.
For More Information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.
Attachments
Vivesto holds a live-streamed business update today November 24
Ämnen i artikeln
Analyser
SBB
Analyser
SBB
Marknadsöversikt
1 DAG %
Senast
1 mån
